Dr. Margrit Schwarz has over 25 years of experience in biopharmaceutical R&D and has directed multiple drug discovery programs from inception to clinical proof-of-concept across multiple indications and modalities, including the anti-PCSK9 antibody Repatha, launched in 2015. Prior executive positions include Chief Operating Officer at Draupnir Bio, and Chief Scientific Officer at Genevant Sciences. Prior to that Dr Schwarz was Global Head External Innovation at Roche, Therapeutic Area Head Cardiorenal at Boehringer Ingelheim, and Director Research at Amgen. Dr Schwarz is a strategic advisor to life science incubators in USA and Switzerland and a Board Director at Altamira Therapeutics. She holds a PhD in Biochemistry from the University of Cologne, Germany, and an MBA from Columbia University, NY.